Eiji Kikuchi

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.

S. Mariathasan, M. Özgüroğlu, J. Arranz, 2023, The Lancet. Oncology.

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

S. Mariathasan, R. Banchereau, D. Vučić, 2024, Cell reports. Medicine.

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.

S. Mariathasan, J. Arranz, M. Mencinger, 2023, The Lancet. Oncology.

Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

T. Powles, G. Iyer, A. Necchi, 2024, Journal of Clinical Oncology.